CLAIMS

1. Use of lurbinectedin in the manufacture of a medicament for the treatment of extensive stage small cell lung cancer (ES-SCLC), wherein the lurbinectedin is to be administered to a patient as part of a combination of lurbinectedin and atezolizumab; wherein lurbinectedin is to be administered at a dose of 3.2 mg/m^2 and atezolizumab is to be administered at a dose of 1200mg; and wherein lurbinectedin and atezolizumab are to be administered on day 1 of a 21 day cycle.

2. The use according to claim 1 wherein lurbinectedin and atezolizumab are to be administered concurrently, separately or sequentially.

3. The use according to any preceding claim, wherein atezolizumab is to be administered before lurbinectedin.

4. The use according to any preceding claim, wherein multiple administrations of either lurbinectedin, or atezolizumab, or both, are to be given.

5. The use according to any preceding claim, wherein lurbinectedin is to be administered by intravenous infusion.

6. The use according to any preceding claim, wherein lurbinectedin is to be administered with an infusion time of up to 24 hours, 1 to 12 hours, or 1 to 6 hours.

7. The use according to any preceding claim, wherein lurbinectedin is to be administered with an infusion time of 1 hour.

8. The use according to any preceding claim, wherein atezolizumab is to be administered by subcutaneous route.

9. The use according to any one of claims 1 to 7, wherein atezolizumab is to be administered by intravenous route.

10. The use according to claim 9, wherein atezolizumab is to be administered with an infusion time of 1 hour; or of 30 minutes for the second and subsequent infusions.

11. The use according to any preceding claim, wherein granulocyte-colony stimulating factor (G-CSF) is to be administered.

12. The use according to claim 11, wherein G-CSF is to be administered on day 1 of a 21 day cycle.

13. The use according to claim 12, wherein the patient is to receive primary prophylaxis with G-CSF starting 24-72 hours after Day 1 of each cycle, and for five days.

14. The use according to any preceding claim comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more cycles.

15. The use according to any preceding claim, wherein the treatment results in reduction in tumour size.

16. The use according to any preceding claim, wherein the treatment results in delay in growth of tumour.

17. The use according to any preceding claim, wherein the treatment results in prolongation of life of the patient.

18. The use according to any preceding claim, wherein the treatment results in delay in disease progression.

19. The use according to any preceding claim, wherein the treatment results in remission.